Role of genetic polymorphisms on neuroplasticity pathways in a cohort of Portuguese patients with Major Depressive Disorder

• Autor(a) principal: Santos, M.
• Data de Publicação: 2022
• Outros Autores: Carvalho, S., Lima, L., Mota-Pereira, J., Pimentel, P., Correia, D., Maia, D., Gomes, S., Cruz, A., Medeiros, R.
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
• Texto Completo: http://hdl.handle.net/10400.22/21698

Growing evidence suggests the implication of brain plasticity in antidepressant drug (AD) efficacy. Several authors have been pointing out the role of the BDNF-TrkB signaling pathway, including the downstream kinases Akt and ERK, and the mTOR pathway in neuroplasticity [1-3]. Furthermore, the prediction of AD response phenotypes of depressed patients treated with AD drugs remains a challenge for clinicians. Although previous studies have suggested that genetic variants may play a key role in the mechanism of Treatment Resistance Depression and Relapse, attempts to identify risk polymorphisms within genes with putative interest in AD response, had a limited success.